Ascentage Pharma
AAPG
14.94
-1.15
-7.15%
Ascentage Pharma
US · AAPG
#3045 by market cap
Listed 2025
14.94
-1.15
-7.15%
Live - 5344 symbols - heartbeat 548s ago
· 2026-10-08 05:05
Pre-market
14.71
-1.54%
After-hours
14.94
0.00%
Overnight
14.70
-1.61%
- Market cap
- 1.40B
- P/E (TTM)i
- -6.37
- P/Bi
- 16.81
- EPSi
- -1.99
- Div yieldi
- 0.00%
- 52W posi
- 2%
Reader sentiment
Are you bullish or bearish on AAPG?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Weak
- Altman Z-Score is -2.62, below the 1.8 "distress zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year -41.46% YoY
Margins
- Gross margin
- 91.48%
- Operating margin
- -208.61%
- Net margin
- -216.47%
Key ratios & quality
- Enterprise valuei
- 895.64M
- Altman Z-Scorei
- -2.62
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 6.81M | 14.51M | 12.45M | 27.91M | 209.71M | 221.98M | 980.65M | 574.12M |
| Gross profit | 6.81M | 12.42M | 10.48M | 24.58M | 187.71M | 191.44M | 951.57M | 525.18M |
| Selling & admin expenses | 89.72M | 149.62M | 118.64M | 191.26M | 328.02M | 376.46M | 383.12M | 599.92M |
| Research & development | 249.57M | 463.88M | 564.57M | 766.49M | 743.10M | 706.97M | 947.25M | 1.14B |
| Operating profit | -323.84M | -582.69M | -663.94M | -869.84M | -849.81M | -872.64M | -369.73M | -1.20B |
| Pretax profit | -346.91M | -1.48B | -675.45M | -832.25M | -887.17M | -932.86M | -395.26M | -1.24B |
| Tax | -1.60M | -1.60M | 2.16M | -49.83M | -4.25M | -7.15M | 10.43M | 6.94M |
| Net profit | -345.31M | -1.48B | -677.61M | -782.42M | -882.92M | -925.71M | -405.68M | -1.24B |
| Basic EPS | -7 | -51 | -13 | -12 | -13 | -13 | -5 | -14 |
| Diluted EPS | -6.67 | -50.76 | -12.56 | -12.28 | -13.40 | -13.12 | -5.36 | -13.96 |
| Line item | 2023-12 | 2024-06 | 2024-12 | 2025-06 | 2025-12 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | -- | -- | -- | -- | -- | -- |
| Research & development | -- | -- | -- | -- | -- | -- |
| Operating profit | -- | -- | -- | -- | -- | -- |
| Pretax profit | -- | -- | -- | -- | -- | -- |
| Tax | -- | -- | -- | -- | -- | -- |
| Net profit | -- | -- | -- | -- | -- | -- |
| Basic EPS | -- | -- | -- | -- | -- | -- |
| Diluted EPS | -- | -- | -- | -- | -- | -- |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 990.22M | 909.11M | 1.08B | 1.89B | 1.64B | 1.34B | 1.47B | 2.94B |
| Cash & ST investments | 971.49M | 878.51M | 1.02B | 1.71B | 1.48B | 1.07B | 1.24B | 2.46B |
| Inventory | -- | -- | 0 | 3.93M | 9.45M | 16.17M | 6.60M | 28.62M |
| Total assets | 1.23B | 1.21B | 1.73B | 2.94B | 2.83B | 2.50B | 2.62B | 3.96B |
| Total current liabilities | 105.27M | 202.06M | 276.15M | 361.11M | 881.15M | 934.17M | 1.17B | 1.64B |
| Short-term debt | 37.59M | 92.19M | 50.56M | 49.45M | 518.38M | 616.40M | 779.06M | 1.22B |
| Long-term debt | -- | -- | 473.06M | 1.03B | 1.27B | 1.17B | 868.64M | 742.33M |
| Total liabilities | 2,240,962,000.00 | 314,575,000.00 | 884,418,000.00 | 1,705,323,000.00 | 2,421,603,000.00 | 2,429,761,000.00 | 2,343,648,000.00 | 2,629,365,000.00 |
| Total equity | -1.01B | 890.48M | 846.62M | 1.23B | 408.66M | 70.63M | 274.16M | 1.33B |
| Retained earnings | -- | -- | -2.77B | -3.56B | -4.44B | -5.37B | -5.77B | -7.01B |
| Line item | 2023-12 | 2024-06 | 2024-12 | 2025-06 | 2025-12 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 1.34B | 1.96B | 1.47B | 1.91B | 2.94B | 2.29B |
| Cash & ST investments | 1.07B | 1.10B | 1.24B | 1.66B | 2.46B | 1.90B |
| Inventory | 16.17M | 10.72M | 6.60M | 8.59M | 28.62M | 64.30M |
| Total assets | 2.50B | 3.11B | 2.62B | 3.05B | 3.96B | 3.24B |
| Total current liabilities | 934.17M | 1.07B | 1.17B | 1.24B | 1.64B | 1.88B |
| Short-term debt | 616.40M | 729.54M | 779.06M | 833.78M | 1.22B | 1.48B |
| Long-term debt | 1.17B | 959.14M | 868.64M | 882.38M | 742.33M | 605.34M |
| Total liabilities | 2,429,761,000.00 | 2,330,631,000.00 | 2,343,648,000.00 | 2,370,235,000.00 | 2,629,365,000.00 | 2,674,869,000.00 |
| Total equity | 70.63M | 776.44M | 274.16M | 675.91M | 1.33B | 565.83M |
| Retained earnings | -5.37B | -5.20B | -5.77B | -6.36B | -7.01B | -7.83B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -237.67M | -460.31M | -609.96M | -604.68M | -653.92M | -726.08M | -111.36M | -1.17B |
| Depreciation & amortization | 18.46M | 26.43M | 27.42M | 28.33M | 62.92M | 93.20M | 93.17M | 86.48M |
| Free cash flow | -287.13M | -541.72M | -861.43M | -1.04B | -890.88M | -782.92M | -135.65M | -1.20B |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock buybacks / issuance | 15.00K | 432.28M | 634.22M | 1.17B | -26.78M | 464.16M | 533.94M | 2.30B |
| Ending cash balance | 957.09M | 738.99M | 1.02B | 1.71B | 1.35B | 1.04B | 893.10M | 1.20B |
| Line item | 2023-12 | 2024-06 | 2024-12 | 2025-06 | 2025-12 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -- | -- | -- | -- | -- | -- |
| Depreciation & amortization | -- | -- | -- | -- | -- | -- |
| Free cash flow | -- | -- | -- | -- | -- | -- |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- |
| Ending cash balance | -- | -- | -- | -- | -- | -- |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -78.02 | -75.18 | -107.45 | -394.66 | -249.80 | -156.46 |
| ROA %i | -38.13 | -121.65 | -46.16 | -33.50 | -30.60 | -34.73 | -15.84 | -37.77 |
| ROIC %i | -- | -- | -57.16 | -41.86 | -37.17 | -42.51 | -20.35 | -48.27 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- | -181.02 | -196.71 |
| EBIT margin %i | -4,553.99 | -10,184.26 | -5,375.04 | -2,921.96 | -397.87 | -376.97 | -33.73 | -205.88 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Current ratioi | 9.41 | 4.50 | 3.91 | 5.22 | 1.86 | 1.44 | 1.26 | 1.79 |
| Quick ratioi | 9.28 | 4.36 | 3.74 | 4.94 | 1.74 | 1.32 | 1.14 | 1.68 |
| Debt / assetsi | 3.42 | 8.42 | 30.60 | 36.88 | 63.34 | 71.81 | 63.74 | 49.95 |
| LT debt / equityi | -- | 1.03 | 56.59 | 83.81 | 311.84 | 1,951.75 | 336.66 | 57.17 |
| Interest coveragei | -8.40 | -345.82 | -106.99 | -48.74 | -15.81 | -8.71 | -5.13 | -21.86 |
| Revenue CAGR (3Y) %i | -- | 23.70 | 25.30 | 60.05 | 143.57 | 161.25 | 227.53 | 39.89 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2023-12 | 2024-06 | 2024-12 | 2025-06 | 2025-12 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -394.66 | -53.13 | -249.80 | -161.86 | -156.46 | -240.30 |
| ROA %i | -34.73 | -11.96 | -15.84 | -37.68 | -37.77 | -46.72 |
| ROIC %i | -42.51 | -13.51 | -20.35 | -47.87 | -48.27 | -59.36 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -376.97 | -32.44 | -33.73 | -277.85 | -205.88 | -218.01 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 1.44 | 1.84 | 1.26 | 1.54 | 1.79 | 1.22 |
| Quick ratioi | 1.32 | 1.83 | 1.14 | 1.53 | 1.68 | 1.18 |
| Debt / assetsi | 71.81 | 54.72 | 63.74 | 56.34 | 49.95 | 64.63 |
| LT debt / equityi | 1,951.75 | 126.64 | 336.66 | 132.49 | 57.17 | 111.33 |
| Interest coveragei | -8.71 | -3.78 | -5.13 | -18.65 | -21.86 | -26.39 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Single-engine
- Sales of products is the largest reported line at 86.96% of revenue, across 3 reported segments.
- The next-largest line, Commercialization rights income, is a distant second at 12.65% - a sharp slowdown here would have little to offset it.
Revenue breakdown most recent period
Business
Sales of products86.96%
Commercialization rights income12.65%
Others0.39%
Region
Chinese Mainland100.00%
Quote time 2026-10-08 05:05:11 · For reference only, not investment advice and not tailored to your situation.